EMERYVILLE and LOS ALTOS, Calif., March 3, 2015 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), an industrial bioscience company, and Genome Compiler Corp., a synthetic biology platform company, have entered into a collaboration agreement to integrate Amyris's automated lab services with Genome Compiler's online design tools and e-commerce platform to enable users to design and order DNA or other biological products seamlessly.
This integration will provide a comprehensive solution from design to delivery of first-of-its-kind integrated DNA design and construction service, which promises to be more automated, less expensive, and more sophisticated than current offerings. Customers will benefit from Genome Compiler's software tools and Amyris's rich libraries of verified genetic parts, DNA construction and editing methods. This joint project is funded in part by a grant from the Binational Industrial Research and Development Foundation (BIRD Foundation), a U.S.-Israeli partnership between private sectors to expand private high-tech industries.
"Amyris is committed to expanding the reach and access of our world leading biofab for advanced DNA construction. We are excited to partner with Genome Compiler to launch an integrated platform for DNA design, construction and lab services. Similar to our recently launched µPharm™ drug discovery and production platform, this new partnership offers some of Amyris's proprietary automated DNA engineering services to pharmaceutical and other biotech companies for scientific discovery and creates opportunities for a new revenue stream for our best-in-class technology platform," said Joel Cherry, President of Research & Development at Amyris.
"At Genome Compiler, we bridge the gap between design and learn iterations in the design-build-test-learn research and development cycle, while providing users with an intuitive, comprehensive synthetic biology platform solution. Making Amyris's best-in-class biofab services broadly available as a service will enable scientists to spend their time where it counts, on the science itself instead of manual bench work," said Omri Amirav Drory, CEO of Genome Compiler.
"Adding Amyris's advanced services to our providers' portfolio will provide the pharma and biotech industries with a comprehensive platform for all their synthetic biology needs. Customers would benefit from direct connections to an array of DNA synthesis providers and automation facilities, and from an extensive suite of advanced bio-informatics tools and genetic repositories, all in one platform," Drory concluded.
About the Companies
Amyris is a global renewable products company providing sustainable alternatives to a variety of non-renewable resources. Amyris uses its innovative bioscience technology to convert plant sugars into hydrocarbon molecules. Amyris creates ingredients and is commercializing its No Compromise® products in the flavors and fragrances, cosmetics, specialty fluids, polymers, lubricants, and fuels industries. Amyris Brasil Ltda., a subsidiary of Amyris, oversees the establishment and expansion of Amyris's production in Brazil. More information about Amyris is available at www.amyris.com.
Genome Compiler is a leader in computer aided design and collaboration platforms for the synthetic biology industry. Based in Los Altos, CA and Tel-Aviv, Israel, Genome Compiler's CAD tool and marketplace platform allows scientists in the biotechnology, agriculture and pharmaceutical industries to design, debug and compile biological code, to develop better bio-based products faster. More information about Genome Compiler is available at www.genomecompiler.com.
This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as the development and commercialization of a planned DNA design and construction service and the anticipated benefits of and customers for such a service) that involve risks and uncertainties. These statements are based on management's current expectations and actual results and future events may differ materially due to risks and uncertainties, including those associated with any delays or failures in development, production and commercialization of products, liquidity and ability to fund capital expenditures, Amyris's reliance on third parties to achieve its goals, and other risks detailed in the "Risk Factors" section of Amyris's quarterly report on Form 10-Q filed on November 7, 2014. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.
Amyris, the Amyris logo, µPharm, and No Compromise are trademarks or registered trademarks of Amyris, Inc. All other trademarks are the property of their respective owners.